Abvc Biopharma (ABVC) Asset Writedowns and Impairment (2022 - 2025)
Abvc Biopharma's (ABVC) quarterly Asset Writedowns and Impairment came in at -$331782.0 in Q4 2025, up 41.12% YoY from -$235108.3 in Q4 2024, and down 1377.9% on a QoQ basis from $25963.0 in Q3 2025.
Abvc Biopharma (ABVC) Asset Writedowns and Impairment (2022 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has 4 years of Asset Writedowns and Impairment data on file, last reported at -$331782.0 in Q4 2025.
- Quarterly Asset Writedowns and Impairment rose 41.12% year-over-year to -$331782.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11460.0 (down 4.44% YoY) and the FY2025 annual result came in at $11460.0, down 4.44% from the prior year.
- Asset Writedowns and Impairment slipped to -$331782.0 in Q4 2025, from $25963.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q4 2023 to a low of -$563477.0 in Q4 2024.
- A 4-year average of $102822.4 and a median of $141761.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 443.98% — and 2024, when it sank 139.78%.
- Tracing ABVC's Asset Writedowns and Impairment over 4 years: stood at -$411830.0 in 2022, then soared by 443.98% to $1.4 million in 2023, then slumped by 139.78% to -$563477.0 in 2024, then jumped by 41.12% to -$331782.0 in 2025.
- The last three Asset Writedowns and Impairment figures came in at -$331782.0 (Q4 2025), $25963.0 (Q3 2025), and $107239.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -331,782.00 |
| Dec 31, 2025 | -331,782.00 |
| Sep 30, 2025 | 25,963.00 |
| Sep 30, 2025 | 25,963.00 |
| Jun 30, 2025 | 107,239.00 |
| Jun 30, 2025 | 107,239.00 |
| Mar 31, 2025 | 210,040.00 |
| Mar 31, 2025 | 210,040.00 |
| Dec 31, 2024 | -563,477.00 |
| Dec 31, 2024 | -563,477.00 |
| Sep 30, 2024 | 213,896.00 |
| Sep 30, 2024 | 213,896.00 |
| Jun 30, 2024 | 185,291.00 |
| Jun 30, 2024 | 185,291.00 |
| Mar 31, 2024 | 176,283.00 |
| Mar 31, 2024 | 176,283.00 |
| Dec 31, 2023 | 1.42 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | -411,830.00 |
| Dec 31, 2022 | -411,830.00 |